Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Sep;97(38):e12403.
doi: 10.1097/MD.0000000000012403.

Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study

Xiao-Wei Xu  1 , Xiao-Xin Wu, Ke-Da Chen, Da-Zhi Chen, Hui-Lin Ou, Jun-Wei Su, Hai-Ying Yu, Hang-Ping Yao, Lan-Juan Li
Affiliations
Observational Study

Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study

Xiao-Wei Xu et al. Medicine (Baltimore). 2018 Sep.

Abstract

Hepatitis C virus (HCV) is one of the most important virus as the cause of liver disease in China. The aim of the present study was to explore whether sofosbuvir and ribavirin-based treatment can cure patients with chronic hepatitis C in eastern China. We examined a cohort of HCV-monoinfected patients and 9 patients agreed to participate in our treatment and research. The patients were diagnosed with chronic hepatitis C with or without cirrhosis. Nine patients including 4 female and 5 male met the requirements for selection and were willing to participate in this experiment. Sofosbuvir and ribavirin-based treatment with or without interferon was given to the patients. Viral loads, cytokines, and chemokines were recorded during treatment and after treatment. After 2 weeks of sofosbuvir and ribavirin-based treatment, the viral load of patients decreased to limits of detection. Eight patients were cured. Patients had rapid virological response (RVR) with undetectable viral load at week 4 and sustained virological response (SVR). The interferon-inducible protein-10 (IP-10) decreased after the treatment. However, the patient with cirrhosis failed, as the virus reappeared during SVR4. At the same time, the IP-10 dramatically increased as the relapse of the HCV virus. In summary, the IP-10 has the potential to be the biomarker for the prognostic of HCV.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The change of IP-10 during the treatment. (A) Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment with interferon; (B) Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment without interferon. IP-10 = interferon-inducible protein-10, SVR = sustained virological response. ∗P < .05.
Figure 2
Figure 2
The change of IP-10 during the treatment. The patient with cirrhosis failed, as the virus reappeared during SVR4. IP-10 = interferon-inducible protein-10, SVR = sustained virological response.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333–42. - PubMed
    1. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–76. - PubMed
    1. Lim SG, Aghemo A, Chen PJ, et al. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol 2017;2:52–62. - PubMed
    1. Razavi H, Robbins S, Zeuzem S, et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325–36. - PubMed
    1. Chen YS, Li L, Cui FQ, et al. A sero-epidemiological study on hepatitis C in China. Chin J Epidemiol 2011;32:888–91. - PubMed

Publication types